Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
FSHD Header Logo
mobile-logo

  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Journey To A Cure
          • 2022 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torchbearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • True Cost of FSHD Study
          • Clinical Trials
          • Donate tissue
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Research We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • Global Collaboration
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Project Mercury
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • JOIN US
  • Donate
  • JOIN US
  • Donate

Epic Bio takes aim at DUX4

Home / FSHD Research / Epic Bio takes aim at DUX4

Posted on: Oct 28, 2022

Leading-edge CRISPR biotech chooses FSHD as its first disease target

Epic Bio, based in the San Francisco Bay Area, announced that FSHD is the first disease it plans to take on with its proprietary CRISPR technology.

Founded by Stanley Qi, PhD, a co-inventor of the Nobel Prize-winning CRISPR patent held by the University of California, Epic Bio has developed a form of CRISPR that can target highly specific regions of the genome without cutting the DNA. Their technology then delivers molecules called Cas9 that modify that part of the genome in order to interfere with a disease-causing process. For example, Cas9 can be designed to activate or inactivate a gene in the target region. This makes it well suited to dial down the expression of DUX4, the gene that causes FSHD.

In laboratory experiments, the “results demonstrate the utility of our dCas to suppress DUX4 expression by up to 95%,” said Amber Salzman, PhD, chief executive officer of Epic Bio. “We view this to be a tremendous step forward to finding a one-and-done treatment for this debilitating disease.

“Following on from this, we have submitted a request to the FDA for a pre-IND meeting to align on the IND submission package and Phase 1 clinical design,” Salzman continued. IND stands for Investigational New Drug, the designation awarded by the US Food and Drug Administration when it allows a new drug to be tested in human clinical trials.

Epic Bio’s proprietary Gene Expression Modulation System (GEMS) platform “integrates its dCas proteins with customized guide RNA and modulator proteins to develop effective and safe approaches to treat diseases,” the company said. “Epic Bio’s dCas proteins are half the size of standard Cas9 proteins, thus enabling Epic Bio to deliver single AAV (adeno-associated virus) vectors to all tissues and organs.” A more efficient viral delivery system would presumably reduce the potential for toxic side effects.

In addition to its initial focus on facioscapulohumeral muscular dystrophy, Epic Bio is conducting research to address alpha-1 antitrypsin deficiency (AATD), heterozygous familial hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors and has raised $55 million in a Series A round.

Signaling the company’s commitment to patients and families, Epic Bio served as presenting sponsor of this year’s Bay Area Walk & Roll, providing financial and logistical support as well as fielding a team of 20 employees who raised additional funds. It feels like the beginning of a beautiful partnership!

Don’t miss out on drug development and clinical trial updates. Make sure to join our PACT registry

Share

Filed Under: FSHD Research

Comments

  1. V says

    October 31, 2022 at 5:54 pm

    This sounds like it has a lot of potential. The problem is that it will probably take decades to get this to those that need it the most. And those that need it the most do not have decades to wait? Also has myoaav not been vetted enough to be used to deliver this. Epic’s CEO in other press discusses derisking by using vectors already used in DMD trials but does not mention myoaav. It seems like myoaav vector to deliver this therapy would be a perfect match.

    Reply
    • S says

      November 16, 2022 at 7:14 pm

      It may take decades depending on many factors but the fact that they’re in a pre IND stage of drug development tells me they’re close to doing a clinical trial which means it’ll probably be within a decade (correct me if I’m wrong) after doing quick research on drug development process. So I don’t think it’ll take “decades” but rather one decade or less.

      Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
    • Journey to a Cure
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

Mail Donations to:

Department 960
PO Box 4106
Woburn, MA 01888-4106

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by